Intellia Therapeutics CEO John Leonard has, for the last couple years, found himself stuck in a financial Groundhog Day.

With a bunch of gene therapy and gene editing programs in clinical trials, CRISPR Therapeutics (NASDAQ: CRSP) has an ...

On Thursday, Bluebird Bio Inc. (NASDAQ:BLUE) reported a third-quarter EPS loss of 31 cents, compared to a loss of 80 cents a ...

As novel gene therapies emerge, there is a complex interplay among their potential benefits, the burdens they may impose and ...

Brian Feth and Jonathan Grinstein go behind the headlines to discuss the impact of a Republican administration on Federal ...